North America Glucagon-Like Peptide-1 (GLP-1) Agonists Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

North America Glucagon-Like Peptide-1 (GLP-1) Agonists Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The North American Glucagon-like Peptide-1 (GLP-1) Agonists Market is set to witness a negative CAGR of around -1% during the forecast period 2022-2027.

The COVID-19 pandemic positively impacted a few segments of the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes’ composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

In North America, till April 2022, the United States is having the highest COVID cases around 82 million, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths of people who are having diabetes. Pandemic emergency has created a rise in remote care from both patients and providers and removed many long-standing regulatory barriers.

The North American region had witnessed an alarming increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates by monitoring their blood glucose levels.

Key Market TrendsLiraglutide Segment holds the highest market share in the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market in 2021.

Liraglutide drug holds the highest market share in the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market with a revenue of more than USD 3 billion. GLP1RAs have been available internationally and are now recommended for use when escalation of treatment for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Liraglutide, sold under the brand name Victoza, is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management.

Liraglutide is used to control high blood sugar levels, either alone or in combination with other medications. It is prescribed to people who have type 2 diabetes. Liraglutide is also used to reduce the risk of a heart attack, stroke, or death in people with type 2 diabetes and heart disease. It works by increasing insulin release in response to high blood sugar levels after a meal and decreasing the amount of sugar produced by the liver. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.

To help make the cost of therapy more manageable, the Victoza Instant Savings Card Program allows the patient to print the savings card for instant use. With this card, the patient pays not more than $25 per Victoza prescription fill, valid for two years. This is equivalent to 24 prescription refills.

However, owing to the increased efficacy of exenatide and semaglutide, and the risks associated with Liraglutide that it causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors it will face tough competition leading to a decline in the sales during the forecast period.

United States is Expected to Dominate the North America Glucagon-like Peptide-1 (GLP-1) Agonists Market

United States holds the highest market share in the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market and is also expected to register a CAGR of around 2% in the forecast period.

An estimated 1.4 million Americans are diagnosed with diabetes every year, according to the American Diabetes Association. Glucagon-like peptide-1 receptor agonists are a class of prescription medications that are effective in the treatment of type 2 diabetes. In addition to lowering blood glucose levels to help treat type 2 diabetes, GLP-1 agonists also resulted in weight loss and other metabolic health benefits. GLP-1 medications are safe, effective, and have relatively few side effects. Any common side effects that patients may experience while taking GLP-1s, such as nausea, are manageable.

In June 2021, the Food and Drug Administration (FDA) approved Semaglutide as a supplement to diet and exercise for the treatment of obesity. Dulaglutide and Exenatide are not approved by the FDA for the treatment of overweight individuals. However, the efficacy of both medications in terms of weight loss has been shown, and they are increasingly being used clinically. Several studies have evaluated the cost-effectiveness of GLP-1RAs in the treatment of diabetes.

The only GLP-1 agonist pill Rybelsus by NovoNordisk was approved for the people in the US in 2019. GLP-1 RAs can be taken alone or in combination with other treatments for type 2 diabetes to improve blood glucose management, i.e., time in range, in addition to lowering blood glucose, they benefit heart health by reducing the risk of heart attack, stroke, and heart-related death. This is important because people with type 2 diabetes are at substantially higher risk of heart disease than those without diabetes.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The North America Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated, with four major manufacturers namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca holding a presence in the North American region. Currently, no generic versions of the GLP-1s are available in the market since the drugs are patent protected.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.